Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Promus stent receives US FDA approval

Boston Scientific : 03 July, 2008  (New Product)
The US Food and Drug Administration (FDA) has approved the Promus Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.
The Promus Stent is a private-labelled Xience V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific under an agreement executed prior to the 2006 acquisition of the former Guidant by Boston Scientific. FDA approval clears the way for Boston Scientific to launch the Promus Stent immediately in the USA.

The Promus Stent expands Boston Scientific's drug-eluting Stent (DES) portfolio, which includes the Taxus Express2 Paclitaxel-Eluting Coronary Stent System (in the US and international markets) and the Taxus Liberte Paclitaxel-Eluting Coronary Stent System (in international markets), making Boston Scientific the only company to offer physicians the choice of two distinct drugs (paclitaxel and everolimus) on separate DES platforms.

'The Promus Stent has shown outstanding deliverability, low late loss and the potential to reduce the need for re-interventions,' said Ted Feldman, MD, FSCAI, director of the Cardiac Catheterization Laboratory at Evanston Northwestern Healthcare in Evanston, Illinois. 'These benefits will make thePromus Stent an attractive new treatment option for US physicians and their patients.'

'FDA approval of the Promus Stent fulfills Boston Scientific's promise of an unprecedented two-drug strategy - two distinct drugs on two highly deliverable Stent platforms,' said Jim Tobin, president and chief executive officer of Boston Scientific. 'The Promus Stent complements our broad DES portfolio and further reinforces Boston Scientific's leadership in the DES market, as well as our commitment to continued innovation and improved patient outcomes.'

The next-generation Promus Stent is a highly deliverable Stent made from cobalt chromium, which allows for thinner struts without sacrificing strength or visibility. The SPIRIT clinical trials indicate that the combination of the polymer/stent platform and the controlled release of the everolimus drug results in excellent deliverability, a strong safety profile, low levels of late loss and improved efficacy, making the Promus (Xience V) Stent a valuable addition to the US drug-eluting Stent market.

Boston Scientific's Promus Stent and Abbott's Xience V Stent are identical products sold by the respective companies under different brand names. The Promus (Xience V) Stent is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (up to 28mm long) with reference vessel diameter of 2.5 to 4.0mm.

As a result of agreements related to its acquisition of Guidant in 2006, Boston Scientific shares the rights to everolimus-eluting Stent technologies with Abbott, including the Xience V Everolimus-Eluting Coronary Stent System (marketed by Boston Scientific as the Promus Stent). The company will continue to market the internally developed paclitaxel-eluting Taxus Stent Systems, which have been the worldwide DES market leaders, implanted in more than four million people. Boston Scientific is also developing paclitaxel-eluting, everolimus-eluting and bare-metal versions of its third-generation Element Stent, which uses a unique platinum-enriched alloy.

The Promus Stent is currently for sale in Europe and certain other international markets.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo